Legal Showdown Halts Apple Watch Series 9 and Ultra 2 Sales: Unveiling the Battle Over Health Tech Innovation.
In a recent development, Apple has encountered a legal roadblock, halting the sale of its Apple Watch Series 9 and Ultra 2 models in the US. This move stems from an ongoing dispute with Massimo, a medical tech company, over proprietary technology related to blood oxygen sensors.
The conflict traces back to Apple’s initial collaboration with Massimo, followed by a contentious hiring spree that roped in key Massimo employees. Subsequently, Apple delved into developing its blood oxygen sensors for the Apple Watch.
Massimo to file lawsuits.
This legal tussle led Massimo to file lawsuits, both in federal district court and with the International Trade Commission. The culmination? A ban on the sale and import of Apple Watch Series 9 and Ultra 2 models, effective just before the festive season, impacting potential holiday sales.
Here’s where the tech community’s interest piqued. The debate revolves around the significance of the blood oxygen sensor feature in these watches. Thoughts on its practicality and accuracy come into question, stirring curiosity about its relevance for the majority of users.
My personal experience with this App
I have used this applications many times on my Apple Watch Series 8 to check my blood oxygen levels after having Covid, I did have some difficulties breathing 6 months after having this Covid. At certain times in the night there was a dip in my oxygen saturation levels,, which became a concern for me as it can cause hypoxemia which is life threatening. Symptoms for Hypoxia include anxiety, confusion, and restlessness. I got a full work up from the NHS who moved very quickly and completed a number of tests. I also thought it would benefit me. I increased my fitness and did breathing exercises everyday. I have been cleared, and the application does not show daily dips in my Oxygen levels.
The timing of this ban is critical.
Apple isn’t sitting idly by. Reports suggest they’re exploring software tweaks to alter the blood oxygen measurement algorithm, potentially seeking compliance with the International Trade Commission’s standards. However, Massimo argues that a hardware change might be imperative.
The timing of this ban is critical, coinciding with Apple’s prime Q4 sales period. If upheld, this restriction could significantly impact Apple’s revenue from the affected models.
Additionally, Apple’s countersuit against Massimo, alleging the release of a smartwatch resembling the Apple Watch, adds another layer to this legal saga.
Understanding what falls under “wearables” in the tech sphere is crucial. While devices like the Apple Watch align with this category, accessories like AirPods might not necessarily fit the definition.
This episode in the tech world underlines the broader challenges companies face in navigating legal landscapes, regulatory approvals, and the intricate timing of product launches.
Follow for more details and its implications follow me on X.